Proteins and Peptides
13 February 2014
Synageva BioPharma(TM) Highlights SBC-103 Data at the Lysosomal Disease Network (LDN) WORLD Symposium(TM)12 February 2014
BioLineRx Announces Positive Preclinical Results for Novel Treatment for Chronic Myeloid Leukemia11 February 2014
BioMarin Announces Selection of NAGLU Fusion Protein Drug Development Candidate BMN 250 for the Treatment of Sanfilippo B (MPS IIIB)10 February 2014
Oramed Submits Phase 2a Protocol to FDA for the Treatment of Type 1 Diabetes with its Oral Insulin Capsule10 February 2014
Protalex Announces Interim Findings from U.S. Phase 1(b) Trial of PRTX-100 in Active Rheumatoid Arthritis Patients5 February 2014
Trevena Initiates Clinical Development of TRV734, a Novel Biased Ligand for Moderate to Severe Pain29 January 2014
Teva Announces U.S. FDA Approval of Three-Times-a-Week COPAXONE® (glatiramer acetate injection) 40mg/mL25 January 2014
GSK receives positive opinion from the CHMP in Europe for once-weekly EperzanTM (albiglutide) for the treatment of type 2 diabetes24 January 2014
Novartis to request re-examination of serelaxin (RLX030) in acute heart failure (AHF) for conditional marketing authorization in EU14 January 2014
BioMarin Doses First Patient in Phase 2 Trial With BMN 111 for the Treatment of Children With Achondroplasia9 January 2014
Trevena Announces Dosing of First Patient in Phase 2b BLAST-AHF Trial of TRV027 for Acute Heart Failure9 January 2014
DiaMedica Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of DM199 in Type 2 Diabetic Patients9 January 2014
Promedior Attains Patient Enrollment Milestone in Phase 2 Clinical Study of PRM-151 in Myelofibrosis8 January 2014
XTL Biopharmaceuticals In-licenses hCDR1, a Phase 2 Clinical Stage Asset for the Treatment of Lupus8 January 2014
Neumedicines’ Study Shows HemaMax, Not Neupogen (G-CSF), Improves Survival Outcomes Following Lethal Irradiation8 January 2014
Adocia launches phase IIa clinical trial for its ultra-fast acting formulation of analog insulin7 January 2014
ERYTECH Positions Its Lead Product in Solid Tumors and Launches a Phase II Clinical Study in Pancreatic CancerNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports